{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:13:18Z","timestamp":1772057598630,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA, Rixensart, Belgium","award":["BoD RSV Study, PO 4450516642"],"award-info":[{"award-number":["BoD RSV Study, PO 4450516642"]}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We compared nationwide data on the clinical characteristics of deceased and non-deceased patients with Respiratory Syncytial Virus (RSV)-coded hospitalization to evaluate potential risk factors for in-hospital fatality by age group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from International Statistical Classification of Diseases (10th Revision)-based German Hospital Statistics for patients from 2010\u20132019 with a primary discharge diagnosis code for RSV-related pneumonia (J12.1), bronchitis (J20.5) or bronchiolitis (J21.0) were assessed by remote data retrieval. Selected underlying conditions and complications were reported stratified by age group and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 612 (0.3% of 205,352) RSV-coded patients died in hospital (103 children &lt;\u200918\u00a0years, 51 adults 18\u201359\u00a0years, 458 seniors &gt;\u200959\u00a0years). Children and adults with underlying chronic cardiovascular, neurological, immunological, or lower respiratory diseases had a higher risk of dying than those without (Odds Ratio 109, 58, 28, 6 in children, and 3, 3, 3, 2 in adults). In seniors, the risk was increased for patients with chronic neurological conditions (OR 1.3) but not for other underlying conditions. Acute respiratory distress syndrome, sepsis and pneumonia increased the risk of a fatal outcome in all age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In-hospital fatality of RSV-coded patients varied considerably with age, chronic conditions and complications. Seniors were the most affected age group and may therefore benefit from the RSV vaccination recommended in Germany since 2024 for all over 75\u00a0years and seniors with pre-existing conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02712-8","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T06:25:29Z","timestamp":1765866329000},"page":"515-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for ICD-10-coded Respiratory Syncytial Virus-associated deaths in hospitalized patients in Germany before the COVID-19 pandemic (nationwide in-patient data, 2010\u20132019)"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-8480","authenticated-orcid":false,"given":"Patricia","family":"Niekler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-0647","authenticated-orcid":false,"given":"David","family":"Goettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-4914","authenticated-orcid":false,"given":"Johannes","family":"Liese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-7106","authenticated-orcid":false,"given":"Andrea","family":"Streng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"2","key":"2712_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0527","volume":"5","author":"CL Hansen","year":"2022","unstructured":"Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. JAMA Netw Open. 2022;5(2):e220527. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0527.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2712_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad513","volume":"10","author":"A Njue","year":"2023","unstructured":"Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023;10(11):ofad513. https:\/\/doi.org\/10.1093\/ofid\/ofad513.","journal-title":"Open Forum Infect Dis"},{"key":"2712_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1186\/s12879-024-09758-3","volume":"24","author":"A Poshtiban","year":"2024","unstructured":"Poshtiban A, Wick M, Bangert M, Damm O. Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review. BMC Infect Dis. 2024;24:844. https:\/\/doi.org\/10.1186\/s12879-024-09758-3.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2712_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/irv.12729","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020;14(6):658\u201370. https:\/\/doi.org\/10.1111\/irv.12729.","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"2712_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.44756","volume":"7","author":"FP Havers","year":"2024","unstructured":"Havers FP, Whitaker M, Melgar M, Pham H, Chai SJ, Austin E, et al. Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023. JAMA Netw Open. 2024;7(11):e2444756. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.44756.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2712_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s15010-023-02122-8","volume":"52","author":"P Niekler","year":"2024","unstructured":"Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010\u20132019). Infection. 2024;52(5):1715\u201324. https:\/\/doi.org\/10.1007\/s15010-023-02122-8.","journal-title":"Infection"},{"key":"2712_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12889-022-12505-5","volume":"22","author":"D Goettler","year":"2022","unstructured":"Goettler D, Niekler P, Liese JG, Streng A. Epidemiology and direct healthcare costs of influenza-associated hospitalizations \u2013 nationwide inpatient data (Germany 2010\u20132019). BMC Public Health. 2022;22:108. https:\/\/doi.org\/10.1186\/s12889-022-12505-5.","journal-title":"BMC Public Health"},{"key":"2712_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70373","volume":"97","author":"G Trifonov","year":"2025","unstructured":"Trifonov G, B\u00fcscher E, Fistera D, Kill C, Risse J, Taube C, et al. Disease burden of RSV infection in adult patients in comparison to influenza virus infection. J Med Virol. 2025;97:e70373. https:\/\/doi.org\/10.1002\/jmv.70373.","journal-title":"J Med Virol"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02712-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:57Z","timestamp":1770021597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02712-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JL received research grants, and\/or speaker\u2019s fees, fees for participation in advisory board meetings from GlaxoSmithKline, Janssen-Cilag, Julius Clinical, Pfizer Pharma, Sanofi Pasteur\/AstraZeneca, SPMSD, MSD, and Bayerisches Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit. AS received research grants, and\/or speaker\u2019s fees, fees for participation in advisory board meetings and travelling grants from GlaxoSmithKline, Pfizer Pharma, Janssen-Cilag, Julius Clinical, MSD, Sanofi Pasteur\/AstraZeneca, and Bayerisches Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit. PN and DG declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee of the Faculty of Medicine at the University of W\u00fcrzburg (Germany) approved the study (No. 20210720-01). All analyses were performed as remote data queries on fully anonymized data from the Federal Statistical Office. Subgroups with less than 3 persons were censored by the Federal Statistical Office for data protection reasons.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate, Consent to publish"}}]}}